Cleared Traditional

Optellum Virtual Nodule Clinic, Optellum software, Optellum platform (K202300) - FDA 510(k) Clearance

Class II Radiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K202300 · Optellum, Ltd. · Radiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2021
Decision
204d
Days
Class 2
Risk

K202300 is an FDA 510(k) clearance for the Optellum Virtual Nodule Clinic, Optellum software, Optellum platform. Classified as Computer-assisted Diagnostic Software For Lesions Suspicious For Cancer (product code POK), Class II - Special Controls.

Submitted by Optellum, Ltd. (Oxford, GB). The FDA issued a Cleared decision on March 5, 2021 after a review of 204 days - an extended review cycle.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2060 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Radiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Optellum, Ltd. devices

Submission Details

510(k) Number K202300 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 13, 2020
Decision Date March 05, 2021
Days to Decision 204 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
97d slower than avg
Panel avg: 107d · This submission: 204d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code POK Computer-assisted Diagnostic Software For Lesions Suspicious For Cancer
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2060
Definition Assist Users In Characterizing Lesions Identified On Acquired Medical Images
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Radiology devices follow this clearance model.

Regulatory Peers - POK Computer-assisted Diagnostic Software For Lesions Suspicious For Cancer

All 20
Devices cleared under the same product code (POK) and FDA review panel - the closest regulatory comparables to K202300.
Brainomix 360 e-ASPECTS
K221564 · Brainomix Limited · Feb 2023
Avenda Health AI Prostate Cancer Planning Software
K221624 · Avenda Health, Inc. · Nov 2022
Koios DS
K212616 · Koios Medical, Inc. · Dec 2021
EchoGo Pro
K201555 · Ultromics, Ltd. · Dec 2020
Rapid ASPECTS
K200760 · Ischemaview, Inc. · Jun 2020
Koios DS for Breast
K190442 · Koios Medical, Inc. · Jul 2019